<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Aspirantskiy Vestnik Povolzhiya</journal-id><journal-title-group><journal-title xml:lang="en">Aspirantskiy Vestnik Povolzhiya</journal-title><trans-title-group xml:lang="ru"><trans-title>Аспирантский вестник Поволжья</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-2354</issn><issn publication-format="electronic">2410-3764</issn><publisher><publisher-name xml:lang="en">Samara State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">24949</article-id><article-id pub-id-type="doi">10.17816/2072-2354.2011.0.5-6.92-96</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The role of rapid virological response in effective outcome prediction of antivirus treatment in patients with chronic hepatitis C</article-title><trans-title-group xml:lang="ru"><trans-title>Значение быстрого вирусологического ответа в прогнозировании эффективности противовирусной терапии хронического гепатита С</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ryumin</surname><given-names>A M</given-names></name><name xml:lang="ru"><surname>Рюмин</surname><given-names>А М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Нижегородская государственная медицинская академия</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2011</year></pub-date><volume>11</volume><issue>5-6</issue><issue-title xml:lang="en">NO5-6 (2011)</issue-title><issue-title xml:lang="ru">№5-6 (2011)</issue-title><fpage>92</fpage><lpage>96</lpage><history><date date-type="received" iso-8601-date="2020-03-11"><day>11</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2011, Ryumin A.M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2011, Рюмин А.М.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="en">Ryumin A.M.</copyright-holder><copyright-holder xml:lang="ru">Рюмин А.М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://aspvestnik.ru/2410-3764/article/view/24949">https://aspvestnik.ru/2410-3764/article/view/24949</self-uri><abstract xml:lang="en"><p>We have studied the role of rapid virological response in treatment outcome in patients with chronic hepatitis C: dependence between sustained virological response and rapid virological response was revealed. Prognostic meaning of other factors (early virological response, viral load and genotype, age of patients and type of therapy) were analyzed too. It was established, that young age, low viral load, genotype 3a and treating with pegylated interferons and ribavirin are associated with higher rate of sustained virological response. The most important predictors of sustained virological response were rapid and early virological responses.</p></abstract><trans-abstract xml:lang="ru"><p>Изучено влияние быстрого вирусологического ответа на исход противовирусной терапии у больных хроническим гепатитом С: выявлена зависимость достижения устойчивого вирусологического ответа от наличия быстрого вирусологического ответа. Проанализировано прогностическое значение других факторов (раннего вирусологического ответа, генотипа вируса, вирусной нагрузки, возраста больных и типа противовирусной терапии) Установлено, что молодой возраст больных, низкая вирусная нагрузка, генотип 3а, лечение больных комбинацией пегилированных интерферонов и рибавирина ассоциированы с большей вероятностью достижения устойчивого вирусологического ответа. Наиболее важным прогностическим фактором оказалось достижение в ходе терапии быстрого и раннего вирусологического ответа.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic hepatitis C</kwd><kwd>antiviral therapy</kwd><kwd>rapid virological response</kwd><kwd>prediction</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хронический гепатит С</kwd><kwd>противовирусная терапия</kwd><kwd>быстрый вирусологический ответ</kwd><kwd>прогнозирование</kwd><kwd>предикторы</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Jensen D.M. et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-960.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kamal S.M. et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 1732-1740.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Yu M.L. et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res 2006; 148: 120-127.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Yu M.L. et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial Hepatology 2008; 47: 1884-1893.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Dalgard O. et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-1265.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Davis G.L. et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Neumann A.U. et al. Hepatitis C viral dynamics in vivo and the antiviral efﬁcacy of interferon-alpha therapy. Science 1998; 282: 103-107.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Yu M.L. et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-559.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Frenci P. et al. Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-458</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.</mixed-citation></ref></ref-list></back></article>
